



Thursday June 13, 2024

09.15-09.50 Registration & Coffee/Tea

09.50-10.00 Welcome

Please Note; Selected abstract-presenters have exactly 15 minutes to present their data, including a few minutes discussion. Please make sure your presentation is on the computer before the session starts.

10.00-11.15 Oral presentation Session 1 (5 speakers)

Session chair: Diede van Ens

PI3K - AKT1 - mTOR activity and BTN3A1 phosphorylation are required for early cancer immune surveillance via Vγ9Vδ2TCR T cell

Peter Brazda, UMC Utrecht

Differential capacity of vaccine adjuvant to stimulate liver tissue-resident memory T cells

Aru Z. Wang, Amsterdam UMC

The immunoregulatory role of Head and Neck Squamous Cell Carcinoma-derived CAFs in a radiotherapeutic setting

Kris Raaijmakers, Radboudumc

CD4+ T-cells produce IFN- γ to license cDC1 for induction of cytotoxic T-cell activity in human tumors

Xin Lei, LUMC

Next generation T cell receptors equipped with ICOS mediate durable anti-tumor activity

Alexandre Marraffa, Erasmus MC

11.15-11.40 Coffee/Tea Break

11:40-12:00 Valorization in practice, invited speaker

Prof. Sjoerd van der Burg, PhD

Medical Oncology, Onco Institute, LUMC, Leiden, Netherlands

“TEIPP targeting for immune escaped cancers, from bench to bed-side”

12.00-13.00 Oral presentation Session 2 (4 speakers)

Session Chair: Simone Kleinendorst

CRISPR-Cas9-mediated knockout of TGF- β R2 improves HPC-NK-cell efficacy against target cells in vitro and renders them insensitive to TGF- β 1

Iris Hagemans, Radboudumc

Intra-tumor neopeptide vaccine together with systemic neopeptide vaccine inhibits tumor growth in a mouse model

Kou Hioki, Erasmus MC

Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL products

Suzanne Castenmiller, Sanquin

The properties of mesenchymal stem cells in the tumor niche direct the outcome of engineered T cell therapy

Angelo Meringa, UMC Utrecht

13.00-14.00 Lunch

14.00-15.00 Oral presentation Session 3 (4 speakers)

Session 3: Tetje van der Sluis

PROTACs as a novel immunotherapeutic tool to boost CTL responses against cancer

Brett Hos, Erasmus MC

Phase I trial investigating neo-adjuvant DURvalumab administered IntraTumorally (DURVIT) in early-stage cervical cancer: safety, toxicity and immunological effects

Marije Strikwerda, Amsterdam UMC

Targeting dysregulated metabolism of tumors using affinity enhanced γ 9 δ 2TCR engineered T cells and bispecific T cell engagers

Mara Nicolassen, UMC Utrecht

Cell cycle inhibition kickstarts CD8+ T cell proliferation by changing metabolism and IL-2 signalling

Floortje van Haften, LUMC

15.00-15.15 Coffee/Tea Break

15.15-16.15 Oral presentation Session 4 (4 speakers)

Session chair: Xiurong Ke

Exploiting bioorthogonal chemistry to study antigen presentation

Amy Kessler, Erasmus MC

Exploring the therapeutic potential of mucosal-associated invariant T (MAIT) cells: optimized expansion and activation of MAIT cells in gastric cancer

Beatriz Ferreira Costa, Amsterdam UMC

Glutaminyl cyclase can modulate therapeutic antibody binding

Anneloes van der Plas-van Duijn, LUMC

Leukotriene B4 acts via interleukin-8 to attract and activate neutrophils to induce IgA-mediated antibody dependent cellular cytotoxicity

Patricia Olofsen, UMC Utrecht

16:15 – 17.45 Laptop sessions

Please note: Each laptop session consists of 3 rounds of 8 min (5 min laptop presentations followed by 3 minutes of discussion). Laptop presenters, please bring a fully charged laptop with your presentation to the session.

16:15-16:45 Laptop Session 1

Table 1: Accelerating clinical translation of Advanced Therapeutic Medicinal Products: the significance of a good manufacturing practice simulation facility

Aiko Ballardini, UMC Utrecht

Table 2: Accelerating clinical translation of Advanced Therapeutic Medicinal Products: the significance of a good manufacturing practice simulation facility

Darshak Bhatt, UMCG

Table 3: SF3B1 mutations affect NK cell function in myeloid neoplasms

Mylene Gerritsen, Radboudumc

Table 4: Methyltransferase DOT1L is important for the development of plasmacytoid dendritic cells in murine bone marrow

Rianne Bouma, Amsterdam UMC

Table 5: Gene-editing of T cells to provide resistance against macrophage-mediated suppression: setting up an in vitro model

Rui M.L. Coelho, Erasmus MC

Table 6: The role of CD56bright and CD56dim NK cells in cellular immunotherapy; are CD56bright cells just precursors or rapid responders?

Els van Hees, LUMC

Table 7: Hematopoietic stem cell-derived NK cells engineered with chimeric antigen receptors as off-the-shelf cancer therapy

Laura Hooijmaijers, Radboudumc

Table 8: Co-evolution of macrophages and fibroblasts in an in vitro model of colorectal cancer

Eline Janssen, Radboudumc

Table 9: T-cell receptors for hematopoietic-restricted minor histocompatibility antigens to treat acute myeloid leukemia after allogeneic stem cell transplantation

Georgia Koutsoumpli, LUMC

Table 10: Identification and characterization of tumor-reactive CD8 and CD4 T cells in hepatocellular carcinoma

Luc Magré, Erasmus MC

Table 11: CAR-mediated target recognition limits TCR-mediated target recognition by TCR- and CAR-dual-receptor-edited T cells

Teuntje Poortvliet, LUMC

Table 12: Comparison of different gangliosides/ α -Galactosylceramide containing liposomes for their capacity to promote adaptive immune responses in spleen and liver

Negisa Seyed Toutouchi, Amsterdam UMC

16:45-17:15 Laptop Session 2

Table 1: CRISPR-Cas9 RNP knockout of ZEB2 in human CD34+ stem cells results in increased cDC1 differentiation

Diede van Ens, Radboudumc

Table 2: CRISPR-cas9 gene engineering for targeted integration of the T cell receptor

Cilia Pothast, LUMC

Table 3: SONATA: Integration of Whole-Genome Sequencing Profiles and Immune Status in Cancer - targets and immune contexture in melanoma and PDAC

Sophie Veenstra, Amsterdam UMC

Table 4: Ex vivo immunopharmacological bio-assay measuring the effect of immune checkpoint inhibition in healthy volunteers as well as cancer and sepsis

Judith Verdonk, Radboudumc

Table 5: CAR T cell therapy against solid tumors by targeting the tumor vasculature

Parvin Akbari, Amsterdam UMC

Table 6: Assessment of the value of tumor CD169+ and CD169- myeloid cells for prognosis and treatment of human hepatocellular carcinoma (HCC)

Patrick Boor, Erasmus MC

Table 7: Immune signature for HER2-low breast cancer

Xi Zhang, LUMC

Table 8: Tumor immune escape: TAM-induced T cell exhaustion and immunosuppression

Eleni Grosu, Radboudumc

Table 9: Multiplex immunohistochemistry to study the role of JAK3 and TEC family kinases in vitiligo and skin cancer

Emma Holtappels, Amsterdam UMC

Table 10: Redirecting pre-existing anti-CMV immunity to selectively target HER2-positive breast cancer cells

Xiurong Ke, UMCG

Table 11: Combining Tumour Infiltrating Lymphocytes, checkpoint inhibition and IFN α induces clinical benefit in metastatic melanoma patients refractory to standard therapies

Anique Verpoorte, LUMC

Table 12: Enhancing neutrophil activity against neuroblastoma using a combination of CD47 blockade and IgA immunotherapy

Ida van der Peet, UMC Utrecht

17:15-17:45 Laptop Session 3

Table 1: A Novel Cancer-Selective hIFN α Immunocytokine Inducing Dual Anticancer Activity

Douwe Samplonius, UMCG

Table 2: Vaccination escaped tumors in mice are re-sensitized to therapeutic vaccination with cisplatin-induced CD8 T cell activation

Pieter Schol, LUMC

Table 3: Exploring the effect of supervised exercise during chemotherapy on immune cell function and tumour infiltration in patients with breast cancer

Anna Ubink, Radboudumc

Table 4: Monitoring the immune microenvironment (MIMIC) of pediatric high grade brain malignancies: insights into T-cell dynamics and checkpoint expression

Joyce Meesters-Ensing, UMC Utrecht

Table 5: Unconventional neo-antigens mediated APOBEC3 mutagenesis in breast cancer

Hamdy Warda, Erasmus MC

Table 6: Assessment of adoptive T cell therapy - using TILs - as a therapeutic option for neuroblastoma

Leyma Wardak, Sanquin

Table 7: The TGF- β /GARP axis in immune suppression of head and neck cancer

Loth Webbink, Amsterdam UMC

Table 8: BOB1-TCR gene therapy for the treatment of multiple myeloma

Johannes Wellershof, LUMC

Table 9: A novel TCR-like antibody-based approach for redirecting pre-existing antiviral immunity to selectively kill cancer cells

Anne van Wijngaarden, UMCG

Table 10: A novel cancer vaccine targeting HER2/3 positive cancers

Xiaolin Wu, Amsterdam UMC

Table 11: Beyond classical antigen presentation: a spatial and genomic analysis of HLA expression in colon cancer immune evasion and patient outcomes

Hehuan Zhu, LUMC

Table 12: Unravelling radiobiological and immunological mechanisms driving effective CAIX-TRT and ICI combination therapy

Simone Kleinendorst, Radboudumc

17.45-18.00 **Break**

18.00-19.00 **Keynote speaker**

Prof. Aurélien Marabelle, MD, PhD

Immunotherapy Translational Research Lab (LRTI), INSERM, Paris, France

**“Primary Resistance to Cancer Immunotherapy:
Lessons Learned from Patients Treated”**

19.00-20.30 **Dinner**

20.30-21.30 **Keynote speaker**

Dr. Jennifer Guerreiro, PhD

Breast Tumor Immunology Laboratory, Dana-Farber Cancer Institute, Boston, USA

**“Leveraging the complexities of tumor associated macrophages
for effective anti-cancer therapy”**

21.30-00.00 **Networking party**



DTIM KWF

Dutch Tumor Immunology Meeting

Friday June 14, 2024

09.00-10.30

Oral presentation Session 5 (6 speakers)

Session chair: Lenneke Cornelissen

A novel CD117xCD3-T cell engager for the elimination of leukemia-initiating stem cells
Giada dal Collo, Erasmus MC

Efficacy of $\alpha\beta$ T cell based immunotherapies relies on CCR5 expression in both CD4+ and CD8+ $\alpha\beta$ T cells
Caroline Schwenzel, UMC Utrecht

Ex vivo tumor testing to assess patient-specific sensitivity to immunomodulatory therapies
Lieke Ceton, Vitrosan

ATM and ATR inhibition increases radiosensitivity and may improve immunogenicity of prostate cancer
Nina van Campen, Radboudumc

The therapeutic potential of V δ 1+ $\gamma\delta$ T-cells in primary colorectal cancer of microsatellite stable patients
Lucrezia Gatti, UMC Utrecht

Development of tissue resident memory T cells in pancreatic cancer
Hester Heimans, LUMC

10.30-11.00

Coffee/Tea Break

11.00-12.00

Valorization Workshop

Drs. Timo Smets, MSc

Valorisatie bureau Amsterdam UMC, Amsterdam, Netherlands

“Valorization: The road from lab findings to patient benefits”

12.00-12.30

Valorization in practice, invited speaker

Dr. Thomas Boltje

Co-founder Synvenio and Glycotherapeutics, Radboud UMC, Nijmegen, Netherlands

“Glycotherapeutics: Targeting glycans as a novel cancer therapy”

12:30-13:30 **Lunch**

13.30-14.10 **Oral presentation Session 6 (2 speakers, 20 min each)**

Session chair: Marij Welters

Contribution of Cancer-Associated Fibroblast subtypes to composition and stiffness of the extracellular matrix in the tumour stroma

Alessandra Cambi, Radboudumc

IgA antibody therapy induces memory immune response against cancer

Maria Tsioumpekou, UMC Utrecht

14.10-15.10 **Keynote speaker 3**

Dr. Anne Rios, PhD

Princess Máxima Center for Pediatric Oncology, Oncode Institute, UMCU, Utrecht, Netherlands

“Organoids; cancer immunity models in motion”

15.10-15.30 **KWF questionnaire, AIO Award Ceremony & Closure**

Thanks to our sponsors for supporting this meeting:

